4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Cap-dependent translation deregulation is linked to various human cancers.
• Malignant pleural mesothelioma (MPM) is an aggressive cancer with limited treatment options.
• The eukaryotic initiation factor 4F (eIF4F) complex plays a crucial role in translation initiation and cancer progression.

Purpose of the Study:

• To investigate the effects of 4EGI-1, a novel inhibitor of cap-dependent translation, on malignant pleural mesothelioma (MPM).
• To determine the therapeutic potential of targeting the eIF4F complex in MPM treatment.
• To identify genes regulated by 4EGI-1 treatment in MPM cells.

Main Methods:

• Treatment of MPM cells and normal mesothelial cells with 4EGI-1.
• Assessment of cell viability and apoptosis induction.
• Analysis of protein levels of 4E-binding protein 1 (4E-BP1), c-myc, and osteopontin.
• Combination therapy studies with pemetrexed or gemcitabine.
• Genome-wide translatome profiling using polysome microarrays.

Main Results:

• 4EGI-1 selectively inhibited cell viability and induced apoptosis in MPM cells compared to normal cells.
• 4EGI-1 treatment led to hypophosphorylation of 4E-BP1 and decreased levels of c-myc and osteopontin.
• Enhanced cytotoxicity was observed when 4EGI-1 was combined with pemetrexed or gemcitabine.
• Translatome analysis identified a significant cohort of genes translationally regulated by 4EGI-1.
• The 4EGI-1-regulated translatome showed an inverse correlation with the translatome regulated by eIF4E overexpression.

Conclusions:

• Inhibition of the eIF4F complex using 4EGI-1 represents a potential therapeutic strategy for MPM.
• 4EGI-1 demonstrates selective anti-cancer effects and enhances the efficacy of standard chemotherapies.
• Genome-wide translational profiling has identified novel target genes for further investigation in MPM treatment.